Loading...
Eculizumab and aHUS: to stop or not
In this issue of Blood, Fakhouri et al(1) provide evidence in a prospective phase 4, multicentric, noncontrolled study that discontinuing eculizumab is safe in most patients with atypical hemolytic uremic syndrome (aHUS) once they achieve complete remission. Risk of relapse was <25% overall, but...
Saved in:
| Published in: | Blood |
|---|---|
| Main Author: | |
| Format: | Artigo |
| Language: | Inglês |
| Published: |
American Society of Hematology
2021
|
| Subjects: | |
| Online Access: | https://ncbi.nlm.nih.gov/pmc/articles/PMC8109016/ https://ncbi.nlm.nih.gov/pubmed/33956069 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood.2020010234 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|